Kura Oncology, INC 10-Q quarterly reports

Kura Oncology announces Q2 2026 results, showing $9.1M in KOMZIFTI net product revenue, but also a net loss of $68.3M.

Kura Oncology announces first quarter 2026 results, with $5.8 million in KOMZIFTI net product revenue and continued investment in pipeline development.

Kura Oncology reports significant clinical progress for its lead cancer therapies, ziftomenib, darlifarnib, and tipifarnib, alongside increased collaboration revenue, despite widening net losses in Q3 2025.

Kura Oncology reports Q2 2025 financial results, highlighting significant progress in its ziftomenib program with FDA Priority Review and positive clinical data, alongside continued operating losses.

Kura Oncology's Q1 2025 results highlight a net loss but significant collaboration revenue from the Kyowa Kirin agreement and progress in clinical trials.

Kura Oncology's Q3 2024 report highlights ongoing clinical trials and financial stability with $455.3 million in cash, cash equivalents, and short-term investments.

Kura Oncology's second quarter 2024 report highlights ongoing clinical trials and financial updates, including a significant cash position.

Kura Oncology's first quarter 2024 results show increased operating expenses offset by higher interest income and a significant private placement, bolstering cash reserves.